Showing 2,871 results

Filters Content type: News, Editors' picks, About HIV Topic: PrEP

Pre-exposure prophylaxis involves people who do not have HIV taking antiretroviral drugs when they are at risk of exposure to HIV in order to prevent infection. The drugs are usually taken as pills (oral PrEP).

Injectable & long-acting PrEP

Lenacapavir PrEP ‘special cases’: young people, missed doses and drug interactions

News
30 July 2025
PrEP

PrEP in Europe

About HIV
July 2025
PrEP policies & guidelines

RFK Jr. reportedly plans to fire the USPSTF for being ‘woke’

Editor's pick
Positively Aware
27 July 2025
Injectable & long-acting PrEP

EMA recommendation on new injection for easier prevention of HIV in the EU and worldwide

Editor's pick
European Medicines Agency
26 July 2025
Injectable & long-acting PrEP

South Africa gets R520-million to buy the twice-a-year anti-HIV jab — but there’s a snag

Editor's pick
Bhekisisa
24 July 2025
Injectable & long-acting PrEP

Does six-monthly PrEP have a future following the collapse of global HIV funding?

News
23 July 2025
Finance & funding

The US cuts challenge African funders and governments to provide new models of PrEP access

News
22 July 2025
Injectable & long-acting PrEP

Lenacapavir and cabotegravir PrEP supported for use in pregnancy and breastfeeding

News
18 July 2025
Finance & funding

Scaling back PEPFAR will leave 700,000 without PrEP and cause 6700 new HIV infections within a year

News
17 July 2025
Injectable & long-acting PrEP

Once-monthly oral PrEP moves into late-stage trials

News
17 July 2025
PrEP science

HIV PrEP Study Finds Modest Bone Loss on FTC/TDF Compared to Cabotegravir

Editor's pick
TheBodyPro
16 July 2025
Injectable & long-acting PrEP

WHO recommends injectable lenacapavir for HIV prevention

Editor's pick
World Health Organization
16 July 2025
Injectable & long-acting PrEP

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

Editor's pick
Merck press release
16 July 2025
Injectable & long-acting PrEP

New Analysis Exposes Path to Affordable Lenacapavir for HIV Prevention

Editor's pick
ITPC Global
16 July 2025
Injectable & long-acting PrEP

Global Fund Secures Access to Breakthrough HIV Prevention Drug Lenacapavir for Low- and Middle-Income Countries

Editor's pick
Global Fund News Releases
10 July 2025
Injectable & long-acting PrEP

Gilead to provide HIV prevention drug to 2 million people in lower-income countries at cost

Editor's pick
STAT (requires free registration)
10 July 2025
PrEP policies & guidelines

Why the new HIV PrEP guidelines from the UK are so exciting

Editor's pick
i-Base
7 July 2025
Pharmaceutical industry

Gilead’s Voluntary License on Lenacapavir: Key Limitations of the License and Recommendations to Improve Access

Editor's pick
Médecins Sans Frontières
7 July 2025
PrEP science

What are the side effects of Truvada used for PrEP?

About HIV
June 2025
Improving HIV care

ECDC releases new standards to improve HIV prevention and care

Editor's pick
European Centre for Disease Prevention and Control (ECDC)
27 June 2025
PrEP policies & guidelines

Supreme Court endorses Obamacare panel that requires free preventive care

Editor's pick
NBC News
27 June 2025
Injectable & long-acting PrEP

Will long-lasting HIV preventive be a game changer—or a missed opportunity?

Editor's pick
Science Magazine
24 June 2025
Vaginal rings & topical PrEP

HIV Prevention Vaginal Ring Recommended for 16-Year-Olds

Editor's pick
Medscape (requires free registration)
24 June 2025
Injectable & long-acting PrEP

HIV protection with just two shots a year: FDA approves Gilead drug

Editor's pick
STAT
19 June 2025